Zepbound is an FDA-approved dual GIP/GLP-1 receptor agonist for chronic weight management that typically produces significant weight loss
GHK-Cu, in concentrations of . micromolar, increased expression of epidermal stem cell markers such as integrins and p in basal keratinocytes in dermal skin equivalents, which according to the authors indicate increased stemness and proliferative potential of basal keratinocytes
Unlike GLP-1 medications, it does not slow stomach emptying but instead works neurologically to help individuals feel less driven to eat, particularly in response to triggers or habits
Monitoring for side effects: Patients starting semaglutide should be closely monitored for serious side effects, like: Pain in the upper part or middle of the stomach that spreads to the back Allergic reaction Decreased urination and swelling of the feet, legs, or ankles Changes in vision Fainting or dizziness Yellow eyes (jaundice), dark urine, or clay-colored stools Rapid heartbeat Sweating, confusion, drowsiness, headache, or blurred vision Customizing a treatment plan: Semaglutide should be tailored to each patients unique health profile, including their cardiovascular risk and comorbidities
